期刊文献+

Developing tissue engineering strategies for liver regeneration 被引量:1

原文传递
导出
摘要 The regenerative function of liver can be destroyed by viral infection,drug poisoning and tumorigenesis,resulting in irreversible damage.Numerous approaches in promoting liver repair intend to replace liver transplantation,which is faced with a shortage of donors.Owing to the significant advantages in cell programming and bioscaf-fold engineering,liver tissue engineering is considered to be the most promising alternative for mimicking liver microstructure,maintaining hepatic function or implanting whole liver.Cell sources gradually develop from pri-mary hepatocytes,tumor cells,stem cell-induced cells to multiple cell coculture formats,spheroids and organoids,which have realized the improvement of cell function,overcome the problem of large-scale cell expansion and avoid the risk of immune rejection.Scaffolds,biocompatible materials are applied as cell carriers,and decel-lularized scaffolds and three-dimensional bioprinting liver pipeline structures are also used to accelerate cell colonization and proliferation.We enumerate sufficient research concerning liver tissue engineering in this re-view,including single and multiple cell sources,implantable and extracorporeal scaffold materials,and so on,providing critical conclusions and future implications of tissue engineering in liver regenerative applications.
出处 《Engineered Regeneration》 2022年第1期80-91,共12页 再生工程(英文)
基金 supported by the National Key Research and Develop-ment Program of China(2020YFA0908200) the Strategic Priority Re-search Program of the Chinese Academy of Science(XDA16021103) the National Natural Science Foundation of China(82100664) the Shen-zhen Fundamental Research Program(JCYJ20190813152616459 and JCYJ20210324133214038) Jiangsu Province Postdoctoral Research Funding Program(2021K116B) Project of Modern Hospital Manage-ment and Development Institute,Nanjing University and Aid project of Nanjing Drum Tower Hospital Health,Education&Research Foundation(NDYG2020047) fundings for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University(2021-LCYJ-PY-46).
  • 相关文献

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部